344 related articles for article (PubMed ID: 31272565)
1. Comparing Cardiovascular Safety of Febuxostat and Allopurinol in the Real World: A Population-Based Cohort Study.
Su CY; Shen LJ; Hsieh SC; Lin LY; Lin FJ
Mayo Clin Proc; 2019 Jul; 94(7):1147-1157. PubMed ID: 31272565
[TBL] [Abstract][Full Text] [Related]
2. Assessment of Cardiovascular Risk in Older Patients With Gout Initiating Febuxostat Versus Allopurinol: Population-Based Cohort Study.
Zhang M; Solomon DH; Desai RJ; Kang EH; Liu J; Neogi T; Kim SC
Circulation; 2018 Sep; 138(11):1116-1126. PubMed ID: 29899013
[TBL] [Abstract][Full Text] [Related]
3. Comparative cardiovascular risk of allopurinol versus febuxostat in patients with gout: a nation-wide cohort study.
Kang EH; Choi HK; Shin A; Lee YJ; Lee EB; Song YW; Kim SC
Rheumatology (Oxford); 2019 Dec; 58(12):2122-2129. PubMed ID: 31098635
[TBL] [Abstract][Full Text] [Related]
4. Cardiovascular Safety of Febuxostat or Allopurinol in Patients with Gout.
White WB; Saag KG; Becker MA; Borer JS; Gorelick PB; Whelton A; Hunt B; Castillo M; Gunawardhana L;
N Engl J Med; 2018 Mar; 378(13):1200-1210. PubMed ID: 29527974
[TBL] [Abstract][Full Text] [Related]
5. Comparative cardiovascular risk in users versus non-users of xanthine oxidase inhibitors and febuxostat versus allopurinol users.
Ju C; Lai RWC; Li KHC; Hung JKF; Lai JCL; Ho J; Liu Y; Tsoi MF; Liu T; Cheung BMY; Wong ICK; Tam LS; Tse G
Rheumatology (Oxford); 2020 Sep; 59(9):2340-2349. PubMed ID: 31873735
[TBL] [Abstract][Full Text] [Related]
6. Comparative Cardiovascular Risks of Febuxostat and Allopurinol in Patients with Diabetes Mellitus and Chronic Kidney Disease.
Huang HH; Chen YY; Fang YW; Liou HH; Wang JT; Tsai MH
Med Sci Monit; 2024 Jun; 30():e944314. PubMed ID: 38865287
[TBL] [Abstract][Full Text] [Related]
7. Protocol of the Febuxostat versus Allopurinol Streamlined Trial (FAST): a large prospective, randomised, open, blinded endpoint study comparing the cardiovascular safety of allopurinol and febuxostat in the management of symptomatic hyperuricaemia.
MacDonald TM; Ford I; Nuki G; Mackenzie IS; De Caterina R; Findlay E; Hallas J; Hawkey CJ; Ralston S; Walters M; Webster J; McMurray J; Perez Ruiz F; Jennings CG;
BMJ Open; 2014 Jul; 4(7):e005354. PubMed ID: 25011991
[TBL] [Abstract][Full Text] [Related]
8. The net clinical benefits of febuxostat versus allopurinol in patients with gout or asymptomatic hyperuricemia - A systematic review and meta-analysis.
Liu CW; Chang WC; Lee CC; Shau WY; Hsu FS; Wang ML; Chen TC; Lo C; Hwang JJ
Nutr Metab Cardiovasc Dis; 2019 Oct; 29(10):1011-1022. PubMed ID: 31378626
[TBL] [Abstract][Full Text] [Related]
9. Cardiovascular safety of febuxostat and allopurinol in patients with gout and cardiovascular comorbidities.
White WB; Chohan S; Dabholkar A; Hunt B; Jackson R
Am Heart J; 2012 Jul; 164(1):14-20. PubMed ID: 22795277
[TBL] [Abstract][Full Text] [Related]
10. Cardiovascular risk and mortality in patients with hyperuricemia treated with febuxostat or allopurinol: a retrospective nation-wide cohort study in Austria 2014-2017.
Weisshaar S; Litschauer B; Reichardt B; Gruber F; Leitner S; Sibinovic S; Kossmeier M; Wolzt M
Rheumatol Int; 2022 Sep; 42(9):1597-1603. PubMed ID: 35589988
[TBL] [Abstract][Full Text] [Related]
11. New Perspectives in Rheumatology: Implications of the Cardiovascular Safety of Febuxostat and Allopurinol in Patients With Gout and Cardiovascular Morbidities Trial and the Associated Food and Drug Administration Public Safety Alert.
Choi H; Neogi T; Stamp L; Dalbeth N; Terkeltaub R
Arthritis Rheumatol; 2018 Nov; 70(11):1702-1709. PubMed ID: 29869840
[TBL] [Abstract][Full Text] [Related]
12. A study comparing the safety and efficacy of febuxostat, allopurinol, and benzbromarone in Chinese gout patients: a retrospective cohort study
.
Zhou Q; Su J; Zhou T; Tian J; Chen X; Zhu J
Int J Clin Pharmacol Ther; 2017 Feb; 55(2):163-168. PubMed ID: 27936522
[TBL] [Abstract][Full Text] [Related]
13. Cardiovascular effects of urate-lowering therapies in patients with chronic gout: a systematic review and meta-analysis.
Zhang T; Pope JE
Rheumatology (Oxford); 2017 Jul; 56(7):1144-1153. PubMed ID: 28379501
[TBL] [Abstract][Full Text] [Related]
14. Cardiovascular safety of febuxostat versus allopurinol among the Asian patients with or without gout: A systematic review and meta-analysis.
Deng JH; Lai PH; Xie LS; Qiu SS; Qiu DS; Zhang JX
Clin Transl Sci; 2024 Mar; 17(3):e13757. PubMed ID: 38488426
[TBL] [Abstract][Full Text] [Related]
15. Cardiovascular safety associated with febuxostat versus allopurinol among patients with gout: Update with accumulated use of febuxostat.
Shin A; Choi SR; Han M; Ha YJ; Lee YJ; Lee EB; Kang EH
Semin Arthritis Rheum; 2022 Oct; 56():152080. PubMed ID: 35973263
[TBL] [Abstract][Full Text] [Related]
16. Long-term cardiovascular safety of febuxostat compared with allopurinol in patients with gout (FAST): a multicentre, prospective, randomised, open-label, non-inferiority trial.
Mackenzie IS; Ford I; Nuki G; Hallas J; Hawkey CJ; Webster J; Ralston SH; Walters M; Robertson M; De Caterina R; Findlay E; Perez-Ruiz F; McMurray JJV; MacDonald TM;
Lancet; 2020 Nov; 396(10264):1745-1757. PubMed ID: 33181081
[TBL] [Abstract][Full Text] [Related]
17. [Febuxostat or allopurinol in patients with gout : Cardiovascular Safety of Febuxostat and Allopurinol in Patients with Gout and Cardiovascular Morbidities (CARES)].
Alten R; Mischkewitz M; Nitschmann S
Internist (Berl); 2020 May; 61(5):530-532. PubMed ID: 32130437
[No Abstract] [Full Text] [Related]
18. Sex difference in heart failure risk associated with febuxostat and allopurinol in gout patients.
Cheng CL; Yen CT; Su CC; Lee CH; Huang CH; Yang YK
Front Cardiovasc Med; 2022; 9():891606. PubMed ID: 36035929
[TBL] [Abstract][Full Text] [Related]
19. Cost Comparison of Urate-Lowering Therapies in Patients with Gout and Moderate-to-Severe Chronic Kidney Disease.
Mitri G; Wittbrodt ET; Turpin RS; Tidwell BA; Schulman KL
J Manag Care Spec Pharm; 2016 Apr; 22(4):326-36. PubMed ID: 27023686
[TBL] [Abstract][Full Text] [Related]
20. Cardiovascular Risks of Probenecid Versus Allopurinol in Older Patients With Gout.
Kim SC; Neogi T; Kang EH; Liu J; Desai RJ; Zhang M; Solomon DH
J Am Coll Cardiol; 2018 Mar; 71(9):994-1004. PubMed ID: 29496000
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
